Sim&Cure Secures €10M to Expand AI-Driven Neurovascular Procedure Planning Globally
Montpellier, France–based medtech innovator Sim&Cure has secured €10 million in a Series extension funding round to accelerate its international growth, expand its software portfolio, and strengthen its research, development, and commercial teams. The new capital infusion comes as the company continues to build momentum in the global neurovascular care market by applying advanced simulation, Digital Twin, and artificial intelligence (AI) technologies to improve planning and outcomes for complex endovascular procedures such as those used to treat cerebral aneurysms.
The €10 million round was supported by historical investors including Elaia and IT Translation Investissement, alongside continued participation from IRDI Capital Investissement, SWEN Capital Partners, Sofilaro, Tudigo, and Holnest — a mix that underscores sustained confidence in Sim&Cure’s technology and vision from both venture capital firms and strategic backers.
Founded in 2014 by CEO and co‑founder Mathieu Sanchez along with medical and technical partners, Sim&Cure has pioneered software solutions designed to assist clinicians in planning neurovascular procedures more safely and efficiently by simulating patient-specific scenarios before intervention. Its flagship product, Sim&Size™, generates a detailed digital representation of a patient’s vascular anatomy, allowing physicians to test multiple treatment strategies and device placements prior to real-world operations — a capability that can reduce procedural risk, saving critical time and improving outcomes.
Sim&Cure’s technology is rooted in both AI and Digital Twin modelling, enabling clinicians to explore numerous “what-if” scenarios in silico that would otherwise require time-consuming manual evaluation or invasive testing. The software is deployed in more than 45 countries and is used by over 700 healthcare professionals, contributing to more than 35,000 treatment planning procedures to date — a figure that underscores the company’s growing adoption in clinical practice.
Cerebral aneurysms — balloon-like bulges in blood vessels in the brain — affect an estimated 3 % to 5 % of the global population and can lead to life-threatening ruptures if not treated effectively. While imaging and interventional techniques have advanced, underdiagnosis and procedural variability remain significant challenges. Sim&Cure’s approach, through enhanced simulation and planning tools, is intended to help address these gaps by empowering physicians with data-rich insights that complement real-world imaging and procedural workflows.
The funding will be used to expand Sim&Cure’s international footprint, with particular focus on the Asia-Pacific region and China, where demand for advanced neurovascular diagnostic and procedural tools is rising rapidly as healthcare systems invest in digital transformation and precision care. The company also plans to accelerate development of its software suite, including enhancements to training and predictive components, and to scale both research efforts and the commercial organisation that supports global customers.
Sim&Cure has diversified its product portfolio beyond core treatment planning with initiatives like Sim&Train, a training platform that uses 3D printing technology, and Sim&Predict, an AI-driven tool for automated detection of cerebral aneurysms in medical imaging. These offerings demonstrate a broader strategy aimed at serving clinicians throughout the lifecycle of care — from early diagnosis to procedural rehearsal and post-intervention learning — and align with industry trends toward integrated, data-enabled care paths.
Sim&Cure’s technology has also been positioned for integration with advanced medical imaging ecosystems, including partnerships with industry leaders such as Siemens Healthineers and Philips that embed simulation tools within next-generation image-guided therapy platforms, enabling clinicians to access simulation insights directly as part of existing clinical workflows.
The company’s success in securing continued investment reflects both its clinical traction and its broader mission to transform endovascular care through preventive, personalised approaches. As healthcare increasingly looks to digital and AI tools to augment physician decision-making, platforms like Sim&Cure’s aim to reduce variability in complex procedures and support better patient outcomes globally.
With the new funding secured, Sim&Cure is poised to expand its reach, enhance its offerings, and contribute to ongoing advances in personalized neurovascular treatment — a domain where precision, insight, and preparation can significantly impact survival and quality of life.
